Atara Biotherapeutics Q3 2026 net loss narrows 48% year over year to $2.23 million

• Atara Biotherapeutics’ third-quarter 2026 net loss narrowed 48% year over year to $2.23 million.
• Total revenues fell 65% year over year to $1.22 million, primarily due to a one-time clinical inventory sale a year earlier.
• Nine-month total costs and operating expenses dropped approximately 83% year over year to $13.43 million.
• The FDA’s tab-cel decision is due March 31, 2027; approval would unlock a $31 million milestone payment from Pierre Fabre.
• Existing cash resources and operating efficiencies are expected to fund planned operations into mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atara Biotherapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611101605BIZWIRE_USPR_____20261110_BW294532) on November 10, 2026, and is solely responsible for the information contained therein.